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• Reduced or micro-gravity
• Radiation
• Limited mass, volume and power
• Limited resources - water, air, food
• Communication lags or blackouts 
(isolation)
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In-Flight Laboratory Analysis 
Goals
• Perform Research on the ISS 
• Demonstrate operations and research capability for Exploration 
Missions
• Novel paradigm for flight surgeons and researchers
• Ensure astronaut health and safety due to injury or illness on extended 
(>30 days) human exploration missions.
• Provide biomedical diagnostics capability to facilitate the recognition 
and treatment of several medical conditions.
• Provide analysis capability of biological fluids (i.e. blood, urine, saliva, 




• Minimize the equipment's mass, volume, consumables, reagents and 
power.
• Ease of operation; minimal training.
• Ideally, should have FDA approval, or have gone through the rigors of 
FDA approval type validation.
• As mission duration lengthens, an analyzer’s capability should be 
readily expanded through software, reagents, dipsticks and/or 
microfluidic cartridges.
• Short start-up time




1. Basic Metabolic Panel
2. Blood Gases Panel
3. Hematology - complete blood cell count with 4-part differential
4.  Cardiac Panel
5. Liver/Renal Panel
6. Urinalysis + urates
ALT - Alanine aminotransferase
AST - Aspartate aminotransferase

























SAGE analysis (serial analysis of gene expression)





















Current ISS Technology Level
*Earlier version (PCBA) iSTAT on ISS 8
1.  Blood Drawn 
on ISS
2.  Sample is 
centrifuged
3.  Sample is 
frozen to wait for 
return
4.  Samples are 
returned on 
SpaceX
5.  Samples 
arrive back at 
JSC





Point of Care Platforms and Multiplexing Cartridges being 
Evaluated at NASA/JSC in March 2013






DeVenCI funded DeVenCI funded
Additional Technologies we are currently evaluating
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Theranos
Luminex
